Editas Medicine Inc SEC Filings

Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).

Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).

Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).

Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.

The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.

Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.

The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.

Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.

The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.

Editas Medicine, Inc. filed a current report describing a change to its equity distribution plans with TD Securities (USA) LLC, doing business as TD Cowen. The company has suspended and terminated the existing prospectus supplement for its “at-the-market” stock offering program under the Sales Agreement.

Editas states it will not sell additional common stock through this program unless and until a new prospectus or prospectus supplement is filed and, if needed, a new registration is declared effective by the SEC. The underlying Sales Agreement with TD Cowen remains in effect.

As of May 26, 2026, Editas had issued and sold 14,327,365 shares of common stock under this at-the-market program, generating aggregate gross sale proceeds of $43.9 million before sales commissions and offering expenses.

Editas Medicine, Inc. filed a current report describing a change to its equity distribution plans with TD Securities (USA) LLC, doing business as TD Cowen. The company has suspended and terminated the existing prospectus supplement for its “at-the-market” stock offering program under the Sales Agreement.

Editas states it will not sell additional common stock through this program unless and until a new prospectus or prospectus supplement is filed and, if needed, a new registration is declared effective by the SEC. The underlying Sales Agreement with TD Cowen remains in effect.

As of May 26, 2026, Editas had issued and sold 14,327,365 shares of common stock under this at-the-market program, generating aggregate gross sale proceeds of $43.9 million before sales commissions and offering expenses.

Editas Medicine, Inc. filed a current report describing a change to its equity distribution plans with TD Securities (USA) LLC, doing business as TD Cowen. The company has suspended and terminated the existing prospectus supplement for its “at-the-market” stock offering program under the Sales Agreement.

Editas states it will not sell additional common stock through this program unless and until a new prospectus or prospectus supplement is filed and, if needed, a new registration is declared effective by the SEC. The underlying Sales Agreement with TD Cowen remains in effect.

As of May 26, 2026, Editas had issued and sold 14,327,365 shares of common stock under this at-the-market program, generating aggregate gross sale proceeds of $43.9 million before sales commissions and offering expenses.

Editas Medicine is offering shares of common stock, pre-funded warrants and accompanying common stock warrants. The prospectus supplement describes the securities' structure, including combined purchase units (each unit pairs a share or pre-funded warrant with a warrant), exercise prices, ownership limitation mechanics (4.99% or 9.99% initially, increaseable to 19.99% after notice), and the limited exercisability windows for the common stock warrants tied to Phase 1 EDIT-401 clinical data or three years from issuance. The filing discloses 97,906,282 shares outstanding as of April 30, 2026, cash and cash equivalents of $123.6 million as of March 31, 2026, Nasdaq listing under the symbol EDIT, and that net tangible book value was $4.4 million ( $0.05 per share) as of March 31, 2026. Use of proceeds is stated as funding EDIT-401 clinical development and manufacturing, plus working capital and general corporate purposes.

Editas Medicine is offering shares of common stock, pre-funded warrants and accompanying common stock warrants. The prospectus supplement describes the securities' structure, including combined purchase units (each unit pairs a share or pre-funded warrant with a warrant), exercise prices, ownership limitation mechanics (4.99% or 9.99% initially, increaseable to 19.99% after notice), and the limited exercisability windows for the common stock warrants tied to Phase 1 EDIT-401 clinical data or three years from issuance. The filing discloses 97,906,282 shares outstanding as of April 30, 2026, cash and cash equivalents of $123.6 million as of March 31, 2026, Nasdaq listing under the symbol EDIT, and that net tangible book value was $4.4 million ( $0.05 per share) as of March 31, 2026. Use of proceeds is stated as funding EDIT-401 clinical development and manufacturing, plus working capital and general corporate purposes.

Editas Medicine is offering shares of common stock, pre-funded warrants and accompanying common stock warrants. The prospectus supplement describes the securities' structure, including combined purchase units (each unit pairs a share or pre-funded warrant with a warrant), exercise prices, ownership limitation mechanics (4.99% or 9.99% initially, increaseable to 19.99% after notice), and the limited exercisability windows for the common stock warrants tied to Phase 1 EDIT-401 clinical data or three years from issuance. The filing discloses 97,906,282 shares outstanding as of April 30, 2026, cash and cash equivalents of $123.6 million as of March 31, 2026, Nasdaq listing under the symbol EDIT, and that net tangible book value was $4.4 million ( $0.05 per share) as of March 31, 2026. Use of proceeds is stated as funding EDIT-401 clinical development and manufacturing, plus working capital and general corporate purposes.

Editas Medicine reported new preclinical results and development plans for EDIT-401, its lead in vivo gene‑editing candidate for hyperlipidemia. In non-human primates, a single dose produced about 90% or greater average reductions in LDL-cholesterol, lipoprotein(a), and apolipoprotein B, key drivers of cardiovascular risk.

At a therapeutically relevant dose of 1.5 mg/kg, EDIT-401 was described as well-tolerated, with no adverse clinical observations, no notable treatment-related liver enzyme elevations, no liver histopathology findings, and a mean functional liver editing rate of 12.4%. Higher doses of 3 mg/kg and 6 mg/kg led to liver enzyme increases and adverse observations at the top dose.

The company plans to submit a Clinical Trial Notification in Australia by mid-2026, aiming to start a first-in-human trial in Heterozygous Familial Hypercholesterolemia later in 2026 and obtain early in vivo human proof-of-concept data by year-end 2026. The proposed Phase 1/2 design includes a Part 1 single ascending dose study in about 18 patients and a Part 2 randomized, placebo-controlled expansion in about 28 patients, with Part 1 topline results expected in 2027. Editas also received FDA pre-IND feedback it believes supports a future U.S. IND for EDIT-401.

Editas Medicine reported new preclinical results and development plans for EDIT-401, its lead in vivo gene‑editing candidate for hyperlipidemia. In non-human primates, a single dose produced about 90% or greater average reductions in LDL-cholesterol, lipoprotein(a), and apolipoprotein B, key drivers of cardiovascular risk.

At a therapeutically relevant dose of 1.5 mg/kg, EDIT-401 was described as well-tolerated, with no adverse clinical observations, no notable treatment-related liver enzyme elevations, no liver histopathology findings, and a mean functional liver editing rate of 12.4%. Higher doses of 3 mg/kg and 6 mg/kg led to liver enzyme increases and adverse observations at the top dose.

The company plans to submit a Clinical Trial Notification in Australia by mid-2026, aiming to start a first-in-human trial in Heterozygous Familial Hypercholesterolemia later in 2026 and obtain early in vivo human proof-of-concept data by year-end 2026. The proposed Phase 1/2 design includes a Part 1 single ascending dose study in about 18 patients and a Part 2 randomized, placebo-controlled expansion in about 28 patients, with Part 1 topline results expected in 2027. Editas also received FDA pre-IND feedback it believes supports a future U.S. IND for EDIT-401.

Editas Medicine reported new preclinical results and development plans for EDIT-401, its lead in vivo gene‑editing candidate for hyperlipidemia. In non-human primates, a single dose produced about 90% or greater average reductions in LDL-cholesterol, lipoprotein(a), and apolipoprotein B, key drivers of cardiovascular risk.

At a therapeutically relevant dose of 1.5 mg/kg, EDIT-401 was described as well-tolerated, with no adverse clinical observations, no notable treatment-related liver enzyme elevations, no liver histopathology findings, and a mean functional liver editing rate of 12.4%. Higher doses of 3 mg/kg and 6 mg/kg led to liver enzyme increases and adverse observations at the top dose.

The company plans to submit a Clinical Trial Notification in Australia by mid-2026, aiming to start a first-in-human trial in Heterozygous Familial Hypercholesterolemia later in 2026 and obtain early in vivo human proof-of-concept data by year-end 2026. The proposed Phase 1/2 design includes a Part 1 single ascending dose study in about 18 patients and a Part 2 randomized, placebo-controlled expansion in about 28 patients, with Part 1 topline results expected in 2027. Editas also received FDA pre-IND feedback it believes supports a future U.S. IND for EDIT-401.

Editas Medicine used this 8-K to share new preclinical results for its in vivo CRISPR candidate EDIT-401, being developed as a potential one-time treatment for hyperlipidemia. In non-human primates, a single dose across 1.5–3.0 mg/kg produced ≥90% mean LDL cholesterol reduction that appeared rapidly and remained durable for about six months.

The company reports this effect was achieved with only 10–40% functional editing of LDLR alleles and at least a six-fold mean increase in hepatic LDLR protein, with no adverse clinical observations at the therapeutically relevant 1.5 mg/kg dose. Mouse pharmacokinetic and pharmacodynamic data suggest dose adjustments may not be needed to achieve LDL-C lowering in heterozygous familial hypercholesterolemia patients, supporting continued advancement toward first-in-human studies.

Editas Medicine reported a Q1 2026 net loss of $25.0 million, sharply improved from $76.1 million a year earlier as prior restructuring and impairment charges rolled off and operating costs declined.

Collaboration and other R&D revenue fell to $2.8 million from $4.7 million. Research and development expense dropped to $17.6 million and general and administrative expense to $10.2 million, reflecting the discontinuation of the reni‑cel program and a large workforce reduction completed in 2025.

The company ended March 31, 2026 with $123.6 million in cash and cash equivalents and an accumulated deficit of about $1.7 billion. Management states this cash should fund operations into the third quarter of 2027 while Editas advances lead in vivo gene‑editing candidate EDIT‑401 toward first‑in‑human studies and early proof‑of‑concept data.

Editas Medicine reported first quarter 2026 results and highlighted progress on its lead in vivo gene-editing program, EDIT-401, for hyperlipidemia and HeFH. Preclinical data showed more than 90% mean LDL-C reduction, and the company plans to start a first-in-human trial in 2026 with early proof-of-concept data expected by year-end and dose-finding topline data in 2027.

Cash and cash equivalents were $123.6 million as of March 31, 2026, which the company expects will fund operations into the third quarter of 2027. Net loss narrowed to $25.0 million, or $0.26 per share, compared with a net loss of $76.1 million, or $0.92 per share, a year earlier, driven by lower R&D and G&A expenses and the absence of prior-year restructuring and impairment charges.

Collaboration and other research and development revenues were $2.8 million, down from $4.7 million in the prior-year quarter, primarily because 2025 included remaining deferred revenue recognized when a collaboration ended. The U.S. Patent and Trademark Office also reaffirmed a prior Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 interference involving patents exclusively licensed to Editas for use in human cells.

Editas Medicine filed its Annual Report on Form 10-K reporting continued focus on in vivo CRISPR gene editing and the nomination of its lead candidate, EDIT-401, an in vivo LDLR upregulation program that produced ~90% mean LDL-C reductions in non-human primates. The company plans an IND or foreign equivalent for EDIT-401 by mid-2026, expects early human proof-of-concept by the end of 2026, and topline dose-finding results in 2027. The report discloses 97,871,999 shares outstanding as of February 27, 2026 and an aggregate market value held by non-affiliates of approximately $191,377,146 as of June 30, 2025. The filing restates strategic priorities: advance EDIT-401, continue HSC and extrahepatic LNP work, and monetize IP via collaborations and licenses.